Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
The discovery and preclinical pharmacology of JNJ-10450232 (NTM-006), a centrally penetrant, non-opioid structural analog of acetaminophen with comparable analgesic and anti-pyretic properties but no evidence of hepatotoxicity.
Journal: Regulatory toxicology and pharmacology : RTP
Published: September 15, 2024
Preclinical safety assessment of JNJ-10450232 (NTM-006), a structural analog of acetaminophen, that does not cause hepatotoxicity at supratherapeutic doses.
Journal: Regulatory toxicology and pharmacology : RTP
Published: August 01, 2022
Metabolism and disposition of JNJ-10450232 (NTM-006) in rats, dogs, monkeys and humans.
Journal: Regulatory toxicology and pharmacology : RTP
Published: July 05, 2022
JNJ-10450232 (NTM-006), A novel non-opioid with structural similarities to acetaminophen, produces relatively long-lasting analgesia after a single dose in patients undergoing 3rd molar extraction.
Journal: Regulatory toxicology and pharmacology : RTP
Published: July 05, 2022
First-in-human study to evaluate the safety, tolerability and pharmacokinetics of a novel analgesic and antipyretic drug with structural similarity to acetaminophen.
Journal: Regulatory toxicology and pharmacology : RTP
Published: November 29, 2021
Application of Real-World Data and the REWARD Framework to Detect Unknown Benefits of Memantine and Identify Potential Disease Targets for New NMDA Receptor Antagonists.
Journal: CNS drugs
Published: December 27, 2020
Sex differences in the role of atypical PKC within the basolateral nucleus of the amygdala in a mouse hyperalgesic priming model.
Journal: Neurobiology of pain (Cambridge, Mass.)
Published: March 25, 2020
The discovery of diazetidinyl diamides as potent and reversible inhibitors of monoacylglycerol lipase (MAGL).
Journal: Bioorganic & medicinal chemistry letters
Published: November 20, 2019
The discovery of azetidine-piperazine di-amides as potent, selective and reversible monoacylglycerol lipase (MAGL) inhibitors.
Journal: Bioorganic & medicinal chemistry letters
Published: November 20, 2019
Pharmacologic Characterization of JNJ-42226314, [1-(4-Fluorophenyl)indol-5-yl]-[3-[4-(thiazole-2-carbonyl)piperazin-1-yl]azetidin-1-yl]methanone, a Reversible, Selective, and Potent Monoacylglycerol Lipase Inhibitor.
Journal: The Journal of pharmacology and experimental therapeutics
Published: August 16, 2019
Discovery and optimization of a novel series of pyrazolyltetrahydropyran N-type calcium channel (Cav 2.2) blockers for the treatment of pain.
Journal: Bioorganic & medicinal chemistry letters
Published: May 15, 2018
Last Updated: 09/26/2026